Early Onset Sepsis Risk Stratification: A Practical Guide for Clinicians

Recent Trends

Over the past several years, neonatal care networks have increasingly shifted from categorical risk-factor–based algorithms to dynamic quantitative risk stratification tools. The neonatal early-onset sepsis (EOS) calculator, first introduced in the 2010s, is now used in many delivery centers, with adoption rates varying by region. Recent audits suggest a growing emphasis on antimicrobial stewardship, driving clinicians to refine thresholds for empiric antibiotic initiation. Concurrently, maternal Group B Streptococcus (GBS) screening remains a mainstay, but its integration with intrapartum antibiotic prophylaxis (IAP) protocols is being reassessed in light of rising antibiotic resistance concerns.

Background

Early-onset sepsis, typically defined as culture-proven infection within the first 72 hours of life, is most commonly caused by GBS and Escherichia coli. Traditional management relied on a checklist of categorical risk factors:

• Maternal fever ≥38.0°C
• C h o r i o a m n i o n i t i s (clinical or histologic)
• Prematurity (≤37 weeks)
• Prolonged rupture of membranes (≥18 hours)
• Positive maternal GBS colonization with inadequate IAP

These criteria, while sensitive, often led to high rates of unnecessary neonatal antibiotic exposure and prolonged NICU stays. In response, multivariate risk stratification—combining clinical exam findings with objective risk factors—has gained traction. The most widely adopted tool uses a Bayesian model to compute a per-patient risk score, guiding decisions on prolonged observation, laboratory testing, or empiric antibiotic treatment.

User Concerns

Clinicians face several practical challenges when applying risk stratification at the bedside:

• Threshold balance – Even a small false‑negative rate can be unacceptable for many practitioners, leading to tension between adhering to the algorithm and clinical intuition.
• Data entry accuracy – The calculator requires precise input of maternal temperature, rupture duration, and gestational age; misentries can skew risk estimates.
• Infection uncertainty – A normal calculator score does not always rule out early sepsis, especially in extremely preterm infants where signs may be subtle.
• Workflow disruption – Implementing a new stratification system requires staff training, real-time decision support, and often a culture change away from “treat all risk factors.”
• Legal and policy concerns – Fear of missed diagnoses may prompt providers to override the algorithm, undermining standardization of care.

Likely Impact

Widespread adoption of validated risk stratification protocols is expected to produce several measurable effects:

• Reduced antibiotic overuse – Most implementations report a 30–50% decline in empiric antibiotic courses without a corresponding increase in missed sepsis.
• Fewer unnecessary NICU admissions – Asymptomatic infants with borderline risk factors can often remain in the well-baby nursery under observation, lowering healthcare costs and family disruption.
• Enhanced surveillance – Clinicians become more systematic about documenting and reassessing clinical signs, improving early detection of late‑onset infection in some settings.
• Need for continuous audit – Centers that adopt strict protocols must regularly review outcomes (e.g., blood culture positivity, antibiotic duration, adverse events) to ensure the algorithm remains appropriate for their local epidemiology.

What to Watch Next

Several developments may refine EOS risk stratification in the near future:

• Machine‑learning models – Multiple groups are developing algorithms that incorporate additional variables (e.g., labor progression markers, maternal inflammatory biomarkers) to improve discriminatory power, especially in preterm populations.
• Rapid biomarker integration – Tests such as serial C‑reactive protein, procalcitonin, or novel host‑response assays may be combined with clinical risk scores to reduce reliance on culture results.
• Electronic health record (EHR) integration – Automated risk calculators embedded in EHRs could reduce data entry errors and provide real‑time decision support, but require careful governance to avoid alert fatigue.
• Multicenter validation studies – Large‑scale prospective studies across diverse populations (including transport infants, outborn babies, and varying sociodemographic backgrounds) will help define generalizability and refine cutoffs.
• Post‑discontinuation surveillance – As some health systems revert to more lenient antibiotic policies, monitoring for unintended increases in actual sepsis rates will be critical to risk‑benefit reassessment.